Jamie L.W. Rhoads MD, MS , Layla Lavasani PhD, MHS , Lawrence Rasouliyan MPH , Marianne Laouri PhD , Megan Noe MD, MPH, MSCE
{"title":"Real-world clinical characteristics and treatment patterns of generalized pustular psoriasis flares","authors":"Jamie L.W. Rhoads MD, MS , Layla Lavasani PhD, MHS , Lawrence Rasouliyan MPH , Marianne Laouri PhD , Megan Noe MD, MPH, MSCE","doi":"10.1016/j.jaad.2025.02.018","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Clinical characteristics and treatment of generalized pustular psoriasis (GPP) flares are poorly understood.</div></div><div><h3>Objective</h3><div>To characterize patients by GPP flare status, quantify flare timing/frequency, and understand peri-flare treatment patterns.</div></div><div><h3>Methods</h3><div>This cohort study utilized electronic health records (2017-2023) from outpatient dermatology clinics in the OMNY Health real-world data platform. Patients were indexed at first GPP diagnosis code; encounter-level GPP flare status was established from previously developed algorithms. Annualized flare rate, time between flares, and peri-flare treatment patterns were described.</div></div><div><h3>Results</h3><div>Four hundred four of 638 patients (63%) experienced ≥1 flare episode. Patients who experienced a flare were more likely to be female, younger, nonwhite, Hispanic/Latino, have infectious/parasitic disease history, and more active GPP. Mean (median) annualized flare rate was 0.91 (0.51) flares/patient/year; mean (median) time between flares was 5.9 (3.8) months. Prescriptions increased from preflare period to flare episode, then decreased during the postflare period. Frequent treatment alterations of off-label biologics and nonsteroidal systemic agents were observed.</div></div><div><h3>Limitations</h3><div>Data were from US-based outpatient dermatology practices; documentation of GPP flares may not have been comprehensive or consistent in this setting.</div></div><div><h3>Conclusion</h3><div>GPP patients continue to experience frequent flares with traditional off-label therapies. Patients' course of treatment was altered frequently, suggesting an unmet need for effective long-term GPP therapies.</div></div>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"92 6","pages":"Pages 1243-1251"},"PeriodicalIF":11.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0190962225002580","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Clinical characteristics and treatment of generalized pustular psoriasis (GPP) flares are poorly understood.
Objective
To characterize patients by GPP flare status, quantify flare timing/frequency, and understand peri-flare treatment patterns.
Methods
This cohort study utilized electronic health records (2017-2023) from outpatient dermatology clinics in the OMNY Health real-world data platform. Patients were indexed at first GPP diagnosis code; encounter-level GPP flare status was established from previously developed algorithms. Annualized flare rate, time between flares, and peri-flare treatment patterns were described.
Results
Four hundred four of 638 patients (63%) experienced ≥1 flare episode. Patients who experienced a flare were more likely to be female, younger, nonwhite, Hispanic/Latino, have infectious/parasitic disease history, and more active GPP. Mean (median) annualized flare rate was 0.91 (0.51) flares/patient/year; mean (median) time between flares was 5.9 (3.8) months. Prescriptions increased from preflare period to flare episode, then decreased during the postflare period. Frequent treatment alterations of off-label biologics and nonsteroidal systemic agents were observed.
Limitations
Data were from US-based outpatient dermatology practices; documentation of GPP flares may not have been comprehensive or consistent in this setting.
Conclusion
GPP patients continue to experience frequent flares with traditional off-label therapies. Patients' course of treatment was altered frequently, suggesting an unmet need for effective long-term GPP therapies.
期刊介绍:
The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.